Abstract 183P
Background
In cancer, inflammation frequently coexists with hypoxia within the tumor microenvironment (TME), often creating an immunosuppressive environment. This hostile milieu is further exacerbated by acidosis, which collectively further hinders effective anti-tumor immune responses. Carbonic anhydrase IX (CAIX) is a well-established hypoxia marker that plays a key role in the pH regulation and adaptation of tumor cells to hypoxia resulting in tumor progression. The CAIX activity contributes to the formation of an acidic environment, which can suppress the function of cytotoxic T cells and other immune cells. While primarily induced by HIF1α under hypoxic conditions, CAIX expression can also be triggered in an inflammatory milieu by IL6 or the COX-2/PGE2 pathway. The goal of this study is to determine the role of CAIX in the regulation of inflammatory and anti-tumor immune responses.
Methods
CAIX+ and CAIX-silenced HT1080 cells were cultured in the presence of a conditioned (inflammatory) medium obtained from MUF spheroids (MUF-CM) under normoxic or hypoxic conditions. RNA samples were analyzed by Clariom, followed by unsupervised clustering. Gene Set Expression Analysis (GSEA) was used to analyze the gene expression. The relation between CAIX level and gene sets identified by GSEA was also analyzed in TCGA SARComa samples and pancreatic cancer (PC).
Results
We found that MUF-CM can upregulate CAIX expression in fibrosarcoma and PC cells even under normoxia. Our analysis revealed that suppression of CAIX leads to upregulation of hallmarks of IFN-α, IFN-γ, and inflammatory response. In silico analysis of TCGA SARC samples confirmed the relationship between lower CAIX expression and higher expression of IFN-α, IFN-γ and inflammation response gene sets, which predicted better overall survival. Moreover, the immune gene sets associated with immune activation and expression of HLA-antigens negatively correlated with CAIX.
Conclusions
Understanding the complex interplay between hypoxia, CAIX, and inflammation is crucial for developing effective cancer treatments. Given the central role of CAIX in this intricate relationship, targeting the function of this enzyme may represent a new opportunity to create a favorable milieu for anti-tumor immune response in the TME.
Legal entity responsible for the study
The authors.
Funding
The Slovak Research and Development Agency 20-0480.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract